Obesity can play a major role in personal health. From exercise and diet to medical intervention, integrated approaches to personal health save lives. $SKYE

We’re in the weight loss era of incretins. GLP-1s and dual agonists are rewriting the rules of metabolic disease. But behind the headlines, expert sentiment reveals a more complex picture: •High discontinuation rates •GI side effects limiting real-world use •Questions

$SKYE Clear strategy. Strong execution. Well-funded. Read our latest shareholder letter for a full update on Skye Bioscience ’s progress and path forward as we build a leading metabolic health company. // bit.ly/4d26OHx

Across interviews with endocrinologists and metabolic experts, a theme emerges: We need more than just “GLP-1, but oral.” We need weight/fat reduction alternatives that: •Target different biological pathways •Complement GLP-1s, not just compete with them •Avoid

We’ve announced the upcoming healthcare and investor conferences Skye will participate in during the month of May. For more details, please see today’s release: ir.skyebioscience.com/news-releases/… $SKYE

CB1 was once a cautionary tale. But that was central CB1. Today’s generation—like nimacimab—is peripherally restricted, preserving powerful metabolic benefits without CNS risk. It targets: •Fat metabolism •Energy balance •Modulation of hunger-regulating hormones And it

Here’s how CB1 inhibition stands apart: •Separate biological pathway - It’s not another gut hormone •Validated target - Decades of human data •Complementary potential - Pairs well with GLP-1s •Better tolerability profile - No GI burden •Possible lean mass preservation - A

At Skye, we’re not chasing the incretin crowd. We’re charting a different course with CB1 inhibition—designed to deliver: •Durable weight loss •A distinct safety and tolerability profile •A complementary approach to the dominant therapies The future of obesity treatment

Improving support, advancing treatment, and breaking stigma around mental health leads to a more supportive world for all. This #MentalHealthAwarenessMonth, we encourage you to raise your voice and help change the conversation around mental health. For more resources, please

Skye will host a conference call on May 8th to discuss our 2025 first quarter financial results. An earnings press release will also be issued after the market closes on May 8th. Please see today’s release for more details: ir.skyebioscience.com/news-releases/… $SKYE

Skye will participate in the 32nd European Congress on Obesity, with a poster presentation on Monday, May 13th. Titled '𝘋𝘦𝘮𝘰𝘯𝘴𝘵𝘳𝘢𝘵𝘪𝘯𝘨 𝘵𝘩𝘦 𝘴𝘶𝘧𝘧𝘪𝘤𝘪𝘦𝘯𝘤𝘺 𝘰𝘧 𝘱𝘦𝘳𝘪𝘱𝘩𝘦𝘳𝘢𝘭 𝘊𝘉1 𝘪𝘯𝘩𝘪𝘣𝘪𝘵𝘪𝘰𝘯 𝘵𝘰 𝘱𝘳𝘰𝘮𝘰𝘵𝘦 𝘸𝘦𝘪𝘨𝘩𝘵 𝘭𝘰𝘴𝘴

Advancing treatments for obesity and other metabolic diseases can lead to better health outcomes and help patients achieve healthier, sustainable weight loss. Learn more about this unmet need and how we're working toward more sustainable outcomes: skyebioscience.com/obesity/ $SKYE

Our poster presentation from the European Congress on Obesity is now available online, demonstrating that achieving strong peripheral CB1 inhibition is sufficient to achieve efficacy, including weight loss. For more details, including comments from CEO Punit Dhillon and Chief

$SKYE Does CB1 Inhibition in the Brain Drive Weight Loss? No. The data presented at ECO this week strongly suggest that peripheral CB1 inhibition alone is sufficient for effective weight loss - central (brain) inhibition only adds neuropsychiatric risk without boosting

Today, we announced a formulation development collaboration with Arecor Therapeutics, aiming to develop a higher concentration formulation of our CB1 inhibitor, nimacimab, using Arecor’s proprietary formulation technology platform, Arestat™. Including comments from Sarah Howell, Chief

Obesity continues to increase in the United States and around the world. Our goal is developing next-generation drugs to treat obesity and help people achieve healthy, sustainable weight loss. Learn more at skybioscience.com. $SKYE

Today, we’ve announced our participation in upcoming investment conferences during the month of June. Including presentations, panel discussions, and 1x1 meetings, read today’s release for more details: ir.skyebioscience.com/news-releases/… $SKYE

At Skye, we're focused on developing next-generation drugs to treat #obesity and other metabolic diseases. As we look beyond the horizons of today’s obesity therapeutics, learn more about our goal of achieving healthier, sustainable outcomes: skyebioscience.com $SKYE

We're looking forward to next week's presentation at the Jefferies Global Healthcare Conference, taking place Thursday morning. To access the live webcast or the post-presentation recording, please visit our website: bit.ly/skyewebcasts $SKYE